Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $6.75 Consensus PT from Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been given an average rating of “Moderate Buy” by the six brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $11.80.

Several research firms have weighed in on CMPX. D. Boral Capital initiated coverage on Compass Therapeutics in a research report on Monday, December 23rd. They issued a “buy” rating and a $32.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, November 11th. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a report on Monday, September 16th.

Compass Therapeutics Price Performance

CMPX opened at $1.46 on Monday. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.34. The firm has a market capitalization of $200.88 million, a P/E ratio of -3.95 and a beta of 0.89. The company’s 50-day moving average is $1.60 and its 200 day moving average is $1.42.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. On average, equities research analysts expect that Compass Therapeutics will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of large investors have recently made changes to their positions in the stock. Rovin Capital UT ADV bought a new stake in shares of Compass Therapeutics during the 3rd quarter valued at $25,000. Intech Investment Management LLC bought a new stake in shares of Compass Therapeutics during the third quarter valued at about $30,000. XTX Topco Ltd purchased a new stake in shares of Compass Therapeutics in the third quarter worth about $37,000. SG Americas Securities LLC boosted its position in shares of Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after acquiring an additional 5,515 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in Compass Therapeutics during the second quarter valued at approximately $41,000. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.